IRCT20180818040823N2Not yet recruitingPhase 2
A clinical trial of a diagnostic radiopharmaceutical (64Cu-DOTA-Trastuzumab) in patients with metastatic breast cancer and HER2-positive
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Enrollment
- 22
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to no limit (—)
- Sex
- Female
Inclusion Criteria
- •Patient with metastatic breast cancer and HER2 receptor
- •No previous treatment with Herceptin
- •Negative estrogen and progesterone receptors
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Active, not recruiting
Phase 1
Ratifying dosage and duration for levo-bupivacaine, a local anaesthetic infusion by the caudal-epidural route in infants 3-6 months.EUCTR2015-000393-34-GBCentral Manchester University Hospitals NHS Foundation Trust10
Recruiting
Not Applicable
Exploratory clinical trial of low-dose radiotherapy in patients treated with immune checkpoint inhibitor and stereotactic body radiotherapy for metastatic cancerKCT0005879Seoul Metropolitan Government Seoul National University Boramae Medical Center40
Completed
Phase 2
Radiation protection effect of curcumin in patients with thyroid cancer treated with 131-Idifferentiated thyroid carcinoma(DTC).Malignant neoplasm of thyroid glandIRCT2016020526377N1Vice Chancellor for Research, Shahid Beheshti University of Medical Sciences20
Completed
Phase 2
The explorative clinical trial of a medicine for treatment of CIN (Cervical Intraepithelial Neoplasia) using lactobacillus to HPV16 positive CIN 2.Cervical Intraepithelial Neoplasia 2 (CIN2)JPRN-UMIN000012229The University of Tokyo Hospital Department of Obstetrics & Gynecology40
Recruiting
Not Applicable
A phase I/II clinical trial of radical radiotherapy using carbon-ion beams with standard adjuvant therapy for early breast cancerbreast cancerJPRN-UMIN000029478QST Hospital, National Institutes for Quantum and Radiological Sciences and Technology30